RxDoctor Payments Data

David Karty, MD

Family Medicine · Olathe, KSNPI 1144272949

Payments from drug & device makers

$1,312in general payments, 2019–2025

Across 47 payments — averaging $27.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$336
  • Sanofi$180
  • AbbVie$177
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$107
  • Sanofi-aventis U.S. LLC$101
  • AstraZeneca$67
  • plus $345 from 8 others

What the payments were for

  • Speaking & faculty fees$21516%
  • Food & beverage$1,09784%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,312 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$82,917
Medicare patients
274
Services billed
1,825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin108$95,693
JanuviaSitagliptin Phosphate88$70,995
OzempicSemaglutide36$49,599
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$29,747
GlyxambiEmpagliflozin/Linagliptin33$24,766
TrulicityDulaglutide23$22,182
Victoza 3-PakLiraglutide14$17,261
TradjentaLinagliptin23$16,762
MyrbetriqMirabegron12$15,997
OxycontinOxycodone Hcl12$14,698
EliquisApixaban24$14,300
LinzessLinaclotide24$13,433
VascepaIcosapent Ethyl46$13,379
JanumetSitagliptin Phos/Metformin Hcl11$9,217
Humalog Kwikpen U-100Insulin Lispro11$5,592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$14$137,221164 claims
Novo NordiskOzempic$63$49,59936 claims
GSKTrelegy Ellipta$336$29,74736 claims
Lilly USA, LLCTrulicity$56$22,18223 claims
PfizerEliquis, Paxlovid$60$17,14238 claims
Astellas Pharma US IncMyrbetriq$37$15,99712 claims
AbbVieLinzess$177$13,43324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Olathe

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →